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Abstract: Mutations in the PARK7 gene, DJ-1, have been reported to cause early-onset and familial Parkinson’s disease 
(PD). The function of DJ-1 and how it contributes to the development of the disease is not clear today, but several studies 
report that DJ-1 is responsive to oxidative stress and important for the maintenance of mitochondria. We have screened 
three coding regions of DJ-1 (exon 2, 5 and 7) in a Swedish Parkinson cohort. The Swedish PD material consisted of 67 
patients with a self reported positive family history of PD and 77 patients with early-onset of disease (50 years old). We 
detected two patients with the previously reported synonymous mutation, Ala167Ala (c.501A>G, rs71653621), in exon 7. 
No Ala167Ala carriers were identified among 213 neurologically healthy Swedish controls. Mechanisms by which the 
synonymous Ala167Ala mutation can have consequences are unknown. It may affect the mRNA stability, secondary 
structure of mRNA, synthesis, turnover, protein folding and function. We could show a 1.3% decrease in DJ-1 mRNA 
folding energy in the A<G substituted sequence compared to the wild type sequence in silico, suggesting a possible small 
effect of Ala167Ala on DJ-1 gene function. This is the first report on an identified DJ-1 mutation in Swedish PD patients. 
Our results, in combination with those of previous studies, strengthen the hypothesis that alterations in DJ-1 are not a 
common cause of familial and early-onset PD world-wide. 
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INTRODUCTION 
  Parkinson’s disease (PD) is a neurodegenerative disorder 
caused mainly by progressive loss of dopamine neurons in 
substantia nigra pars compacta. Pathways proposed to trigger 
onset of PD include oxidative stress and dysfunction of mito-
chondria [1]. The PARK7 gene, DJ-1, has been reported to 
be responsive to oxidative stress and important for the main-
tenance of mitochondria [2,3]. DJ-1 was originally identified 
and described as an oncogene [4] and the 189 amino acid 
protein is highly conserved across species [5]. The DJ-1 pro-
tein is abundantly expressed throughout the body and in the 
normal human brain it is moderately expressed in neurons 
and in astrocytes throughout the CNS [6,7]. Oxidative modi-
fications of DJ-1 have been reported in brain tissue from 
patients with sporadic PD and Alzheimer’s disease compared 
to controls [8]. It has been suggested that DJ-1 protect neu-
rons against oxidative stress by acting as a redox-dependent 
chaperone [9]. The protein is normally found in the cyto-
plasm and oxidative stress promotes relocation to mitochon-
dria where it protects against mitochondrial toxins [2,10]. 
DJ-1 can bind RNA in an oxidative-dependent manner and 
the DJ-1/RNA complex dissociates after oxidative stress 
[11,12]. Structural studies of DJ-1 have suggested oxidation 
of Cysteine at residue 106 to be essential for DJ-1 to exert its 
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full activities [3]. However it remains to be shown how oxi-
dation of Cys106 leads to antioxidative and/or cytoprotective 
effects through conformational changes and how PD associ-
ated DJ-1 mutations affect these processes. 
  In 2001 the PARK7 locus on chromosome 1p36 was 
linked to a family with autosomal recessive early-onset 
parkinsonism (AREP) in the Netherlands [13]. The following 
year the same locus was linked to a family with AREP in 
Italy [14]. Two mutations in DJ-1 were later reported to co-
segregate with disease, a 14kb deletion in the Dutch PD fam-
ily and a Leu166Pro substitution in the Italian PD family, 
and both lead to loss of gene function [5]. The DJ-1 muta-
tions are recessively inherited and result in PD with early-
onset, overall mutations identified to date are rare, causing 
~1% of the PD cases world-wide and no mutations have 
been reported in Swedish PD cases [15]. In the Caucasian 
PD population the majority of DJ-1 mutations leading to 
changes in the amino acid sequence have been found in ex-
ons 2, 5 and 7 [16]. We therefore sequenced these exons in a 
Swedish Parkinson cohort to search for known and new vari-
able sites.  
MATERIAL AND METHODS 
Subjects 
  Exons 2, 5 and 7 and the exon/intron borders of DJ-1 
were sequenced in a Swedish PD material consisting of 144 
individuals (mean age 64.3 years, 56.9% men). 77 of the PD 
patients had an early disease onset (50 years old) and 67 of DJ-1 Mutations in Sweden  The Open Neurology Journal, 2011, Volume 5    9 
the patients had a self reported positive family history of PD 
in one or more first-, second- or third-degree relatives (15 of 
these patients had early-onset as well). 66 of the early-onset 
cases have previously been investigated for possible changes 
in copy numbers in exon 1, 3, 5 and 7 of DJ-1 although no 
aberrations were detected  [17]. These patients were screened 
for Parkin point mutations and Parkin, -Synuclein, UCH-L1 
and PINK1 exon copy number aberration as well. No known 
PD causing Parkin mutation or copy number aberration was 
found. Control subjects consisted of 213 neurologically 
healthy participants from the Stockholm area (mean age 75.8 
years, 41.3% men). The material was obtained after informed 
oral and written consent and approval of the local ethics 
committee at Karolinska Institutet and University of Goth-
enburg. All PD subjects met the United Kingdom Parkin-
son's Disease Society Brain Bank Criteria for PD except that 
more than one affected relative was allowed [18]. DNA was 
extracted from blood according to standard protocol.  
Sequencing 
  Samples from PD patients were analyzed with automated 
capillary sequencing. Polymerase chain reaction (PCR) was 
carried out using Taq DNA polymerase and the following 
primer sequences: exon 2 forward primer 5´-TCTCAGGG 
TTGCAATGAAAG-3´; reverse primer 5´-AAGCGTTAA 
ATGTGAGCAGTG-3´, exon 5 forward primer 5´-
AAATAGGTCAGAGAGCTTGTGG-3´; reverse primer 5´-
TCAAACCATCGAATGAAAGG-3´ and exon 7 forward 
primer 5´-ACAGTGTTGGGTTTATATGCTG-3´; reverse 
primer 5´-GGACAGCGACTTCTGAACAC-3´. 40 cycles 
were run at 95°C for 45 s, 56°C for 40 s and 72°C for 1 min 
followed by 7 min terminal elongation at 72°C. The PCR 
products were 337 bp (exon 2), 258 bp (exon 5) and 378 bp 
(exon 7) of the DJ-1 gene. Purification of the amplified 
fragment was performed by using QIAquick® PCR Purifica-
tion kit (Qiagen, Hilden, Germany). The isolated DNA 
fragments were sequenced using a DTCS kit followed by 
automated capillary gel electrophoresis (CEQ 2000 system, 
Beckman Coulter Inc., Fullerton, CA, USA), following the 
provider’s instruction. 
Pyrosequencing 
  To specifically screen neurologically healthy controls for 
the Ala167Ala mutation in exon 7 we used pyrosequencing 
[19] and the following primer sequences; forward primer 5´-
AGACGGCCTGATTCTTACAAGC-3´; reverse primer 5´-
GGCCTGTTTCTCTAAGTGATCG-3´ and sequencing 
primer 5´-CTTCGAGTTTGCGC-3´. The reverse primer was 
biotinylated at the 5´-end.  Positive controls for the 
Ala167Ala mutation were used in the pyrosequencing assay 
to guarantee accuracy of the method as well as water con-
trols.  PCR was carried out with Taq DNA polymerase to 
amplify a 175 bp fragment. 45 cycles were run at 95°C for 
20 s, 57°C for 20 s and 72°C for 30 s followed by 7 min ter-
minal elongation at 72°C, after which the biotinylated PCR 
product was immobilized on streptavidin-coated beads by 
mixing at 2500 rpm for 10 min at room temperature accord-
ing to manufacturer’s instructions. The immobilized DNA 
template was then captured onto filter probes (PyroMark 
Vacuum Prep Tool, Biotage AB, Uppsala, Sweden). The 
filter probes were flushed with 70% ethanol, denaturation 
solution, washing buffer and the single-stranded template 
was annealed to a reverse sequencing primer at 80°C for 2 
min followed by cooling to room temperature. All solutions 
used in sample preparation were prepared according to 
manufacturer’s instructions (Biotage AB, Uppsala, Sweden). 
Samples were analyzed on an automated pyrosequencer us-
ing a PSQ 96 System together with single SNP Software and 
SNP Reagent Kits (Biotage AB, Uppsala, Sweden). 
Prediction of mRNA Secondary Structure 
  To evaluate the possible effect of the identified 
Ala167Ala mutation on the DJ-1 mRNA level, the secondary 
structure was predicted using the publicly available online 
software mfold version 3.2 [20,21]. Partial DJ-1 mRNA se-
quences of 141 nucleotides including flanking sequences (70 
nucleotides) on either side of the mutation were analyzed and 
compared to the wild type sequence.  
RESULTS 
  In 144 PD cases we identified the synonymous mutation, 
Ala167Ala (c.501A>G, rs71653621), in exon 7 of DJ-1 in 
two PD patients (Fig. 1 and Table 1). No Ala167Ala carriers 
were identified among the 213 neurologically healthy Swed-
ish controls. To test whether the synonymous Ala167Ala 
substitution has a possible effect on the secondary structure 
of DJ-1 mRNA we performed a structure analysis in silico. 
Our results indicated a small decrease in mRNA folding en-
 
 
 
 
 
 
 
 
 
 
Fig. (1). Results from automated capillary sequencing of exon 7 in DJ-1 including the Ala167Ala (c.501A>G, rs71653621) mutation using a 
reverse sequencing primer (T>C). a) A homozygous wild type (WT) T/T, Ala167Ala carrier and b) a heterozygous (Het) T/C, Ala167Ala 
carrier. 10     The Open Neurology Journal, 2011, Volume 5  Anvret et al. 
ergy (1.3%) in the A>G substituted sequence compared to 
the wild type sequence (Table 2). 
DISCUSSION 
  The number of DJ-1 mutations described today is low 
and they account for only a few PD cases in different popu-
lations [16]. In the present study, we have searched for muta-
tions in exon 2, 5 and 7 and in the exon/intron borders of DJ-
1, since variations have been reported in these regions [22]. 
We detected a heterozygote Ala167Ala mutation in two out 
of 144 Swedish PD patients, but no Ala167Ala carriers were 
identified among the 213 neurologically healthy controls. 
This is the first report on DJ-1 mutations identified in a 
Swedish PD material. The Ala167Ala mutation was previ-
ously identified in a PD patient (homozygote carrier) from 
the United Kingdom and in a patient from a North American 
material with Caucasian/Hispanic origin (heterozygote car-
rier) [22,23]. One of the Swedish Ala167Ala carriers was 
diagnosed with Alzheimer’s disease as well (Table 1), which 
is in agreement with the reports that DJ-1 has been impli-
cated in Alzheimer’s disease [8]. Mechanisms by which the 
synonymous Ala167Ala mutation may have consequences 
on the protein level and predispose to disease are not well 
understood. The DJ-1 protein has been suggested to act in 
multiple pathways and hypothesized that loss of the protec-
tive function of DJ-1 in dopaminergic neurons can lead to 
neurodegeneration [24]. Several possibilities have been sug-
gested for synonymous mutations including alterations of 
mRNA stability, secondary structure, transcriptional activity, 
or changes in protein synthesis, folding, levels, turnover 
and/or function [25]. We found a small decrease in mRNA 
folding energy (1.3%) comparing the mutated Ala167Ala 
sequence with the wild type sequence, suggesting a possible 
effect of Ala167Ala on DJ-1 gene function [26]. However, 
no strong conclusions can be drawn from the artificial condi-
tions used for modeling secondary structures in silico. 
  The frequency of DJ-1 mutations has been reported to 
vary among PD populations with different ethnic origin, 
Caucasian: 0.91%, Asian: 3.03%, Arab: 0.74% and Ashke-
nazi Jews: 1.96% and copy number variations in DJ-1 have 
so far only been reported in the Caucasian PD population 
(0.54%) [16]. We found the Ala167Ala mutation in two PD 
patients in our Swedish cohort, but no other genetic variant 
in any of the three investigated exons. The observed DJ-1 
mutation frequency (1.4%) is in agreement with findings in 
other Caucasian PD populations.  
CONCLUSION 
  This is the first report on a DJ-1 mutation identified in 
Swedish PD patients. Based on the results of the screening in 
our Swedish cohort as well as the results from other studies, 
it appears clear that mutations in DJ-1 are a rare cause of 
familial and early-onset PD world-wide.  
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